Ifng-Venus-Luc
Nomenclature
C57BL/6JSmo-Ifngem1(IRES-Venus-Luci)Smoc
Cat. NO.
NM-KI-18041
Strain State
Repository Live
Gene Summary
Gene Symbol
Ifng
Model Description
Validation Data
Fig1.MC38-OVA tumor volumes in Ifng-Venus-Luci reporter mice treated or not with anti-PD-1 mAb. Arrows indicate treatment days.
Fig2. In vivo imaging validation of MC38-OVA tumors in Ifng-Venus-Luci reporter mice treated or not with anti-PD-1 mAb.
In PBS treated control tumor, the IFNγ signal increased as the tumor growing. In anti-PD1 treated tumor, increased average BLI (Bioluminescent imaging) of IFNγ was shown 48h post the first dose compared to control group; as the tumor regression upon PD1 treatment, the IFNγ signal in tumor decreased as well.
The data is provided by Crownbio.
You may also like
Workshop：Progress and Advances in Preclinical immuno-Oncology Research
SMOC’s Annual Progress and Advances in Preclinical immuno-Oncology Research: The workshop is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.
Learn moreShanghai Model Organisms Center Inc has licensed CRISPR-Cas9 technology from Broad Institute
On Dec 16, 2018, Broad Institute and Shanghai Model Organisms Center Inc (SMOC) has entered into a non-exclusive license agreement under which Broad has granted SMOC worldwide rights to commercialize a service platform for genetically modified mouse models under Broad's intellectual property.
Learn moreCustomizing Mouse Models: Delivering in 100 Days to Speed Up Your Research!
At GenoBioTX, we understand that the lengthy wait times for gene-modified mouse models can hinder your research progress. Traditional methods often require 6-9 months, leading to delays and increased costs. That’s why we’re thrilled to introduce our innovative service designed to streamline this process and deliver results faster.
Learn more
